Evidence map›Paper›PMID 32378241›Full record

ArticleLasers in surgery and medicine2021

Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study.

Emil A Tanghetti, David J Goldberg, Jeffrey S Dover, Roy G Geronemus, Zane Bai, Nancy Alvandi, Stuart D Shanler

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Lasers in surgery and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Rosacea: Practical Guidance and Challenges for Clinical Management.Clinical, cosmetic and investigational dermatology · 2024
    Review
  4. Review
  5. Review
  6. Rosacea Treatment: Review and Update.Dermatology and therapy · 2021
    Review
  7. Updates and Best Practices in the Management of Facial Erythema.Clinical, cosmetic and investigational dermatology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Emil A TanghettiCenter for Dermatology and Laser Surgery, 5601 J Street, Sacramento, California, 95819.
David J GoldbergSkin Laser & Surgery Specialists of New York and New Jersey, 115 E 57th Street, #400, New York, New York, 10022.
Jeffrey S DoverSkin Care Physicians, 1244 Boylston Street (Route 9), Chestnut Hill, Massachusetts, 02467.
Roy G GeronemusLaser & Skin Surgery Center of New York, 317 East 34th Street, New York, New York, 10016.
Zane BaiAllergan, Giralda Farms, Dodge Drive, Madison, New Jersey, 07940.
Nancy AlvandiAllergan, Giralda Farms, Dodge Drive, Madison, New Jersey, 07940.
Stuart D ShanlerAclaris Therapeutics, Inc., 640 Lee Road, Suite 200, Wayne, Pennsylvania, 19087.
Allergan (United States) · USLaser and Skin Surgery Center of New York · USAclaris Therapeutics (United States) · USCenter for Dermatology and Laser Surgery · USChestnut Hill College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe objectives of this study were to evaluate the safety, tolerability, and efficacy of oxymetazoline hydrochloride cream, 1% (oxymetazoline) when used as an adjunctive treatment with energy-based therapy for patients with moderate to severe facial erythema associated with rosacea. STUDY DESIGN/MATERIALS AND

methodsIn this Phase 4, multicenter, interventional, open-label study, eligible patients received one of four energy-based therapies (potassium titanyl phosphate laser, intense pulsed light therapy, pulsed-dye laser Vbeam Perfecta, or pulsed-dye laser Cynergy) on day 1 and day 29 and once-daily application of oxymetazoline on days 3 through 27 and days 31 through 56. Improvement from baseline in Clinician Erythema Assessment (CEA) score, patient satisfaction measures, incidence of treatment-emergent adverse events (TEAEs), and worsening from baseline on dermal tolerability assessments and the Clinician Telangiectasia Assessment (CTA) were assessed. Data were summarized using descriptive statistics.

resultsA total of 46 patients (mean age, 51.1 years; 78.3% female) enrolled in this study. Similar numbers of patients received each of the energy-based therapies in addition to oxymetazoline. All patients demonstrated an improvement from baseline in CEA during the study with 39 of 43 evaluable patients (90.7%) demonstrating an improvement 6 hours posttreatment on day 56. Most patients were satisfied or very satisfied with treatment at the end of the study. All TEAEs were mild or moderate in severity. Some patients experienced worsening in dermal tolerability assessment symptoms (range: 4-21 patients; 8.7-45.7%). Worsening in CEA and CTA were each reported by three patients (6.5%) at any time during the study.

conclusionsTreatment with oxymetazoline as adjunctive therapy with energy-based therapy was safe, well tolerated, and reduced facial erythema in patients with moderate to severe persistent facial erythema associated with rosacea. Lasers Surg. Med. © 2020 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.

Indexed as

OxymetazolineRosaceaErythemaFemaleHumansMaleMiddle AgedSkin CreamTreatment OutcomeOxymetazolineerythemaintense pulsed light therapyoxymetazolinepotassium titanyl phosphate laserspulsed dye lasersrosaceatelangiectasiastopical administration

Identifiers

PMID32378241
PMCPMC7891417
OpenAlexW3023377757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.